

Adge Pharma, Cyan Bio advance treatments for rare paediatric diseases in Asian countries

26 April 2022 | News

The territories include Korea, Greater China, Japan, India and Southeast Asian countries



Adge Pharmaceuticals has entered into a license agreement with South Korea-based Cyan Bio, Inc. Cyan will receive exclusive rights for commercialization of elocalcitol in key territories in Asia for the treatment of the Rett Syndrome and Osteogenesis imperfecta.

The territories include Korea, Greater China, Japan, India and Southeast Asian countries. In parallel with the licensing agreement, Cyan will make an equity investment in Adge.

Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 clinical trials. Furthermore, its mechanism of actions are highly relevant to addressing pathogenesis of multiple rare diseases including Rett Syndrome and Osteogenesis imperfecta that Adge is targeting as priority indications.

Rett syndrome is a neurodevelopmental disorder that is caused by a mutation in the *MECP2* gene and almost exclusively affects girls. While Osteogenesis imperfecta, also known as brittle bone disease, is a group of genetic diseases that primarily affect the bones. People with this condition have bones that fracture easily, often from mild trauma or with no apparent cause.